FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
2 days ago
Business Wire via QuoteMedia